Reducing the risk of stroke in diabetes: What have we learned that is new?

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Given the significant public health impact of stroke and the identification of nonmodifiable (age, gender, race/ethnicity) and modifiable (blood pressure, diabetes, lipid profile, and life-style) risk factors, early prevention strategies should be initiated. When a patient suffers a stroke, the focus of care becomes prevention of future events. For the patient with diabetes, comprehensive medical management of ischaemic stroke (primary or secondary prevention) includes antihypertensive and lipid-lowering therapy, as well as antiplatelet therapy. Despite the cerebrovascular risk reduction with these modalities, clearly new agents are needed. The Heart Outcomes Prevention Evaluation (HOPE) study provides compelling evidence that treatment with the angiotensin converting enzyme inhibitor, ramipril, can further reduce the risk of stroke in high-risk patients by mechanisms other than lowering blood pressure. In HOPE, patients were normotensive at baseline. Therefore, for the first time, in a patient population without left ventricular dysfunction, the effects of an ACE inhibitor ramipril on reducing stroke risk were demonstrated. Ramipril 10 mg achieved a significant 33% reduction in stroke among patients with diabetes. Based on the HOPE study, the recently published American Heart Association guidelines for the primary prevention of stroke recommend ramipril to prevent stroke in high-risk patients and in patients with diabetes and hypertension. Wide-scale adherence to these guideline recommendations for the prevention of primary and secondary stroke would significantly benefit the public health.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume4
Issue numberSUPPL. 1
StatePublished - Apr 17 2002
Externally publishedYes

Fingerprint

Stroke
Ramipril
Primary Prevention
Secondary Prevention
Angiotensin-Converting Enzyme Inhibitors
Public Health
Blood Pressure
Guideline Adherence
Lipids
Left Ventricular Dysfunction
Risk Reduction Behavior
Antihypertensive Agents
Life Style
Therapeutics
Guidelines
Hypertension
Population

Keywords

  • Atherosclerosis
  • High-density-lipoprotein cholesterol
  • Hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Reducing the risk of stroke in diabetes : What have we learned that is new? / Sacco, Ralph L.

In: Diabetes, Obesity and Metabolism, Vol. 4, No. SUPPL. 1, 17.04.2002.

Research output: Contribution to journalArticle

@article{38eb7dfa96d845e9bbee6e555f1ef676,
title = "Reducing the risk of stroke in diabetes: What have we learned that is new?",
abstract = "Given the significant public health impact of stroke and the identification of nonmodifiable (age, gender, race/ethnicity) and modifiable (blood pressure, diabetes, lipid profile, and life-style) risk factors, early prevention strategies should be initiated. When a patient suffers a stroke, the focus of care becomes prevention of future events. For the patient with diabetes, comprehensive medical management of ischaemic stroke (primary or secondary prevention) includes antihypertensive and lipid-lowering therapy, as well as antiplatelet therapy. Despite the cerebrovascular risk reduction with these modalities, clearly new agents are needed. The Heart Outcomes Prevention Evaluation (HOPE) study provides compelling evidence that treatment with the angiotensin converting enzyme inhibitor, ramipril, can further reduce the risk of stroke in high-risk patients by mechanisms other than lowering blood pressure. In HOPE, patients were normotensive at baseline. Therefore, for the first time, in a patient population without left ventricular dysfunction, the effects of an ACE inhibitor ramipril on reducing stroke risk were demonstrated. Ramipril 10 mg achieved a significant 33{\%} reduction in stroke among patients with diabetes. Based on the HOPE study, the recently published American Heart Association guidelines for the primary prevention of stroke recommend ramipril to prevent stroke in high-risk patients and in patients with diabetes and hypertension. Wide-scale adherence to these guideline recommendations for the prevention of primary and secondary stroke would significantly benefit the public health.",
keywords = "Atherosclerosis, High-density-lipoprotein cholesterol, Hypertension",
author = "Sacco, {Ralph L}",
year = "2002",
month = "4",
day = "17",
language = "English",
volume = "4",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Reducing the risk of stroke in diabetes

T2 - What have we learned that is new?

AU - Sacco, Ralph L

PY - 2002/4/17

Y1 - 2002/4/17

N2 - Given the significant public health impact of stroke and the identification of nonmodifiable (age, gender, race/ethnicity) and modifiable (blood pressure, diabetes, lipid profile, and life-style) risk factors, early prevention strategies should be initiated. When a patient suffers a stroke, the focus of care becomes prevention of future events. For the patient with diabetes, comprehensive medical management of ischaemic stroke (primary or secondary prevention) includes antihypertensive and lipid-lowering therapy, as well as antiplatelet therapy. Despite the cerebrovascular risk reduction with these modalities, clearly new agents are needed. The Heart Outcomes Prevention Evaluation (HOPE) study provides compelling evidence that treatment with the angiotensin converting enzyme inhibitor, ramipril, can further reduce the risk of stroke in high-risk patients by mechanisms other than lowering blood pressure. In HOPE, patients were normotensive at baseline. Therefore, for the first time, in a patient population without left ventricular dysfunction, the effects of an ACE inhibitor ramipril on reducing stroke risk were demonstrated. Ramipril 10 mg achieved a significant 33% reduction in stroke among patients with diabetes. Based on the HOPE study, the recently published American Heart Association guidelines for the primary prevention of stroke recommend ramipril to prevent stroke in high-risk patients and in patients with diabetes and hypertension. Wide-scale adherence to these guideline recommendations for the prevention of primary and secondary stroke would significantly benefit the public health.

AB - Given the significant public health impact of stroke and the identification of nonmodifiable (age, gender, race/ethnicity) and modifiable (blood pressure, diabetes, lipid profile, and life-style) risk factors, early prevention strategies should be initiated. When a patient suffers a stroke, the focus of care becomes prevention of future events. For the patient with diabetes, comprehensive medical management of ischaemic stroke (primary or secondary prevention) includes antihypertensive and lipid-lowering therapy, as well as antiplatelet therapy. Despite the cerebrovascular risk reduction with these modalities, clearly new agents are needed. The Heart Outcomes Prevention Evaluation (HOPE) study provides compelling evidence that treatment with the angiotensin converting enzyme inhibitor, ramipril, can further reduce the risk of stroke in high-risk patients by mechanisms other than lowering blood pressure. In HOPE, patients were normotensive at baseline. Therefore, for the first time, in a patient population without left ventricular dysfunction, the effects of an ACE inhibitor ramipril on reducing stroke risk were demonstrated. Ramipril 10 mg achieved a significant 33% reduction in stroke among patients with diabetes. Based on the HOPE study, the recently published American Heart Association guidelines for the primary prevention of stroke recommend ramipril to prevent stroke in high-risk patients and in patients with diabetes and hypertension. Wide-scale adherence to these guideline recommendations for the prevention of primary and secondary stroke would significantly benefit the public health.

KW - Atherosclerosis

KW - High-density-lipoprotein cholesterol

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=0036205168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036205168&partnerID=8YFLogxK

M3 - Article

C2 - 11843952

AN - SCOPUS:0036205168

VL - 4

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - SUPPL. 1

ER -